MEDI4736 + MEDI4736 + Tremelimumab + Standard of Care
Phase 3CompletedDevelopment Stage
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Sep 9, 2015 → Nov 13, 2020
About MEDI4736 + MEDI4736 + Tremelimumab + Standard of Care
MEDI4736 + MEDI4736 + Tremelimumab + Standard of Care is a phase 3 stage product being developed by AstraZeneca for Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN. The current trial status is completed. This product is registered under clinical trial identifier NCT02369874. Target conditions include Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02369874 | Phase 3 | Completed |
Competing Products
20 competing products in Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN